Abstract

HOMOHARRINGTONINE: A NASCENT PHYTOCHEMICAL FOR CANCER TREATMENT (A REVIEW)

Vishal Bhagwan Badgujar*, Mohammed Tahir Ansari, Mohd Syafiq Abdullah and Sangita Vishal Badgujar

ABSTRACT

Recently homoharringtonine (HHT) was approved in October 2012 by FDA for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia. The time spend for this approval was more than 40 years, one of the historical for any drug to be approved by FDA. Looking towards potential of HHT, we aim to review its long journey. This review involves sources, chemistry, semisynthetic formulation, extraction, new methods of production, characterization, mechanism, and clinical development of homoharringtonine (HHT). The compiled data will be helpful for the researchers to focus on different aspects of HHT and its analogues. The data may prove useful for anticancer research and areas of research yet to be discovered.

Keywords: homoharringtonine, omacetaxine mepesuccinate, chronic myeloid leukemia, Cephalotaxus harringtonia.